Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TNB-486 |
Synonyms | |
Therapy Description |
TNB-486 is a bispecific T-cell redirecting antibody that binds to CD19 on tumor cells as well as CD3, and may lead to tumor cell killing and inhibition of tumor growth (Blood (2019) 134 (Supplement_1): 4070). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TNB-486 | TNB486|TNB 486|AZD0486|AZD-0486|AZD 0486 | CD19 Antibody 19 CD3 Antibody 86 | TNB-486 is a bispecific T-cell redirecting antibody that binds to CD19 on tumor cells as well as CD3, and may lead to tumor cell killing and inhibition of tumor growth (Blood (2019) 134 (Supplement_1): 4070). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04594642 | Phase I | TNB-486 | A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 2 |